Secondly, mechanisms of resistance to immunotherapy include alternative immune checkpoint expression (e.g. TIM3, LAG3), insufficient tumor mutation burden or neoantigens to trigger an effective immune response, insufficient priming, inadequate T cell recruitment and infiltration, the presence of regulatory T cells and/or tumor-associated macrophages, including MDSCs, that coordinate an immunosuppressive tumor microenvironment, or loss of tumor antigen-presenting machinery/loss of interferon signalling. The gene discussed is LAG3; the disease is neoplasm.